Transparency and Dermatologic Device Approval by the US Food and Drug Administration
Open Access
- 1 March 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (3) , 273-280
Abstract
The US Food and Drug Administration (FDA) evaluates and approves Class III medical devices through its premarket approval (PMA) process. The agency classifies devices that “support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury” as Class III devices.1,2 Such devices pose a greater risk to patient health than Class I or Class II devices and are therefore subject to the FDA’s most stringent regulatory requirements.1,2Keywords
This publication has 28 references indexed in Scilit:
- Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013JAMA Internal Medicine, 2016
- How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?Clinical Orthopaedics and Related Research, 2015
- FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012JAMA, 2014
- Dermal fillers in aesthetics: an overview of adverse events and treatment approachesClinical, Cosmetic and Investigational Dermatology, 2013
- Diagnosis of high-voltage conductor fractures in Sprint Fidelis leadsHeart Rhythm, 2013
- Management of impending necrosis associated with soft tissue filler injections.2011
- Learning from Our Mistakes? Testing New ICD TechnologyNew England Journal of Medicine, 2008
- The American filler experience – a response to Dr BaumannJournal of Cosmetic Dermatology, 2005
- Recalls of Foods and Cosmetics Due to Microbial Contamination Reported to the U.S. Food and Drug AdministrationJournal of Food Protection, 2000
- On the supposed occurrence of uroleucic acid in the urine in some cases of alkaptonuriaThe Journal of Physiology, 1907